U.S. Markets closed

Exelixis initiates Phase 3 pivotal trial of cabozantinib

Exelixis announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor. The primary endpoint for the trial is progression-free survival.